Changes

no edit summary
Line 366: Line 366:  
|PMID:27090007; PMID:26061753; PMID:25263767 PMID:26061754; PMID:24335697; PMID:25664944;PMID:26061753; PMID:26941959; PMID:26824661 PMID:26061751   
 
|PMID:27090007; PMID:26061753; PMID:25263767 PMID:26061754; PMID:24335697; PMID:25664944;PMID:26061753; PMID:26941959; PMID:26824661 PMID:26061751   
 
|-
 
|-
 +
|
 
|Glioblastoma , grade IV, IDH mutant
 
|Glioblastoma , grade IV, IDH mutant
 
|'''Gain:''' 1/1q, 6p<br>
 
|'''Gain:''' 1/1q, 6p<br>
Line 431: Line 432:  
|-
 
|-
 
|
 
|
 +
|Classic ependymoma (no WHO grade assigned)
 +
|'''Gain:''' 1q, 5, 7, 9, 11, 18, 20<br>
 +
'''Loss:''' 1p, 3, -6/6q, 9p, 13q, 17, 22
 +
|'''Loss:''' CDKN2A/CDKN2B (rare); NF2<br>
 +
'''Mutation:''' NF2 (esp. in spinal tumors)   
 +
|Usually intracranial, spinal tumors (myxopapillary) are rare; 80% of pediatric tumors develop in posterior fossa (PF); Supratentorial tumors preferentially show monosomy 9; 1q gain is unfavorable prognostic indicator in PF tumors; spinal tumors associated with NF2 mutation (germline)
 +
|PMID:25965575; PMID:22338015; PMID:28371821
 +
|-
 +
|
 +
|Subependymoma, WHO grade I <br>
 +
(intracranial or spinal)
 +
|Typically '''balanced genomes'''<br>
 +
'''Loss:''' -6/6q in spinal tumors 
 +
|No diagnostic mutations
 +
|Favorable prognosis
 +
|WHO CNS Tumors (2016)<br>
 +
PMID:21959044; PMID:21840481
 +
|-
 +
|
 +
|Myxopapillary ependymoma, WHO grade I  (spinal)
 +
|'''Aneuploidy:''' multiple chromosomes lost and gained
 +
|'''Mutation:''' NF2 (including germline) in spinal tumors
 +
|More common in adults
 +
|PMID:25965575; PMCID:3991130; PMID:20425037 PMID:25957288; PMID:25965575; PMID:22516549
 +
|-
 +
|
 +
|Ependymoma, RELA fusion-positive, WHO grade II or III<br>
 +
(intracranial)
 +
|'''Gain:''' 1q<br>
 +
'''Aneuploidy:''' multiple chromosomes lost and gained<br>
 +
'''Chromothripsis:''' chromosome 11 (70% of supratentorial tumors)
 +
|'''Fusion:''' c11orf95-RELA (supratentorial tumors)<br>
 +
'''Loss:''' CDKN2A/B (may help distinguish from other supratentorial ependymomas)
 +
|Unfavorable prognosis
 +
|PMID:25965575; PMID:24553141; PMID:28371821
 +
|-
 
|
 
|
 +
|Anaplastic ependymoma (no WHO grade assigned; intracranial or spinal)
 +
|'''Epigenetic studies''' suggest range of abnormalities: balanced or unbalanced genomes
 +
|'''Mutation:''' NF2 (including germline) in spinal tumors<br>
 +
'''Fusion:''' RELA fusions, YAP1 fusions can correspond to anaplastic histology
 +
|Mostly intracranial tumors, rarely in spinal cord
 +
|PMID: 25965575; PMID:27022130